Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 57 patents granted in the last 365 days
United Arab Emirates University maintains 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are split between 2 distinct examiners and 2 distinct art units. This arrangement shows that the university's current research and patenting efforts are being evaluated by different technical experts across multiple divisions of the USPTO.
JERICA KATLYNN WILSON is the busiest examiner, with 1 pending office action. Because there are 2 pending office actions across 2 distinct examiners, the workload is distributed with each examiner managing exactly one case. This lack of concentration means that the university manages separate prosecution tracks, each with its own examiner and art unit requirements.
The use of 2 distinct art units indicates that the 2 pending office actions cover different aspects of the Biotechnology & Pharmaceuticals field. Practitioners should be aware that the outcomes in one art unit may not influence the other. The busiest examiner, JERICA KATLYNN WILSON, handles 1 pending office action, which represents a portion of the total pending activity for the university's portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILSON, JERICA KATLYNN | 1 | 61.4% | +39.1% |
| MACCAGNO, PIERRE L | 1 | 23.8% | +30.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18766050 | SYSTEM AND METHOD FOR DIAGNOSTICS AND FINDING TREATMENTS FOR MILD COGNITIVE IMPAIRMENT, DEMENTIAS AND NEURODEGENERATIVE DISEASES | MACCAGNO, PIERRE L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18925790 | NEW USE OF RECA INHIBITOR AND DERIVATIVE COMPOUNDS FOR CANCER TREATMENT | WILSON, JERICA KATLYNN | — |
| 18766050 | SYSTEM AND METHOD FOR DIAGNOSTICS AND FINDING TREATMENTS FOR MILD COGNITIVE IMPAIRMENT, DEMENTIAS AND NEURODEGENERATIVE DISEASES | MACCAGNO, PIERRE L | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 3687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18925790 | NEW USE OF RECA INHIBITOR AND DERIVATIVE COMPOUNDS FOR CANCER TREATMENT | WILSON, JERICA KATLYNN | 1621 | §103 | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18766050 | SYSTEM AND METHOD FOR DIAGNOSTICS AND FINDING TREATMENTS FOR MILD COGNITIVE IMPAIRMENT, DEMENTIAS AND NEURODEGENERATIVE DISEASES | MACCAGNO, PIERRE L | 3687 | §101 | Non-Final OA | — | Pending | Jul 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial